 | • レポートコード：MRC2Q12-16786 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、頭蓋内治療薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 頭蓋内治療薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 頭蓋内治療薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 頭蓋内治療薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの頭蓋内治療薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の頭蓋内治療薬の売上および2028年までの予測に焦点を当てています。 頭蓋内治療薬のグローバル主要企業には、Novartis AG、BioMarin、CORESTEM Inc.、Alaunos Therapeutics, Inc.、Apic Bio、Stemedica Cell Technologies, Inc.、Voyager Therapeutics、Bayer AG、Abeona Therapeutics、Spark Therapeuticsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 頭蓋内治療薬市場は、タイプとアプリケーションによって区分されます。世界の頭蓋内治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 細胞治療、遺伝子治療、酵素補充療法 【アプリケーション別セグメント】 病院、専門クリニック、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 頭蓋内治療薬製品概要 - タイプ別市場（細胞治療、遺伝子治療、酵素補充療法） - アプリケーション別市場（病院、専門クリニック、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の頭蓋内治療薬販売量予測2017-2028 - 世界の頭蓋内治療薬売上予測2017-2028 - 頭蓋内治療薬の地域別販売量 - 頭蓋内治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別頭蓋内治療薬販売量 - 主要メーカー別頭蓋内治療薬売上 - 主要メーカー別頭蓋内治療薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（細胞治療、遺伝子治療、酵素補充療法） - 頭蓋内治療薬のタイプ別販売量 - 頭蓋内治療薬のタイプ別売上 - 頭蓋内治療薬のタイプ別価格 ・アプリケーション別市場規模（病院、専門クリニック、その他） - 頭蓋内治療薬のアプリケーション別販売量 - 頭蓋内治療薬のアプリケーション別売上 - 頭蓋内治療薬のアプリケーション別価格 ・北米市場 - 北米の頭蓋内治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の頭蓋内治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの頭蓋内治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の頭蓋内治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の頭蓋内治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の頭蓋内治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の頭蓋内治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の頭蓋内治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの頭蓋内治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の頭蓋内治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Novartis AG、BioMarin、CORESTEM Inc.、Alaunos Therapeutics, Inc.、Apic Bio、Stemedica Cell Technologies, Inc.、Voyager Therapeutics、Bayer AG、Abeona Therapeutics、Spark Therapeutics ・産業チェーン及び販売チャネル分析 - 頭蓋内治療薬の産業チェーン分析 - 頭蓋内治療薬の原材料 - 頭蓋内治療薬の生産プロセス - 頭蓋内治療薬の販売及びマーケティング - 頭蓋内治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 頭蓋内治療薬の産業動向 - 頭蓋内治療薬のマーケットドライバー - 頭蓋内治療薬の課題 - 頭蓋内治療薬の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Intracranial Treatment Drug estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Intracranial Treatment Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Intracranial Treatment Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Intracranial Treatment Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Intracranial Treatment Drug include Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, Inc., Apic Bio, Stemedica Cell Technologies, Inc., Voyager Therapeutics, Bayer AG and Abeona Therapeutics, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Intracranial Treatment Drug companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Intracranial Treatment Drug market. Further, it explains the major drivers and regional dynamics of the global Intracranial Treatment Drug market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Novartis AG
BioMarin
CORESTEM Inc.
Alaunos Therapeutics, Inc.
Apic Bio
Stemedica Cell Technologies, Inc.
Voyager Therapeutics
Bayer AG
Abeona Therapeutics
Spark Therapeutics
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Intracranial Treatment Drug Segment by Type
Cell Therapy
Gene Therapy
Enzyme Replacement Therapy
Intracranial Treatment Drug Segment by Application
Hospital
Specialty Clinic
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Intracranial Treatment Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Intracranial Treatment Drug market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Intracranial Treatment Drug, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Intracranial Treatment Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Intracranial Treatment Drug revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Intracranial Treatment Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Intracranial Treatment Drug revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, Inc., Apic Bio, Stemedica Cell Technologies, Inc., Voyager Therapeutics, Bayer AG and Abeona Therapeutics, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Intracranial Treatment Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Intracranial Treatment Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Intracranial Treatment Drug revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Intracranial Treatment Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Cell Therapy
1.2.3 Gene Therapy
1.2.4 Enzyme Replacement Therapy
1.3 Market by Application
1.3.1 Global Intracranial Treatment Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Intracranial Treatment Drug Market Perspective (2017-2028)
2.2 Intracranial Treatment Drug Growth Trends by Region
2.2.1 Intracranial Treatment Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Intracranial Treatment Drug Historic Market Size by Region (2017-2022)
2.2.3 Intracranial Treatment Drug Forecasted Market Size by Region (2023-2028)
2.3 Intracranial Treatment Drug Market Dynamics
2.3.1 Intracranial Treatment Drug Industry Trends
2.3.2 Intracranial Treatment Drug Market Drivers
2.3.3 Intracranial Treatment Drug Market Challenges
2.3.4 Intracranial Treatment Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Intracranial Treatment Drug Players by Revenue
3.1.1 Global Top Intracranial Treatment Drug Players by Revenue (2017-2022)
3.1.2 Global Intracranial Treatment Drug Revenue Market Share by Players (2017-2022)
3.2 Global Intracranial Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Intracranial Treatment Drug Revenue
3.4 Global Intracranial Treatment Drug Market Concentration Ratio
3.4.1 Global Intracranial Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Intracranial Treatment Drug Revenue in 2021
3.5 Intracranial Treatment Drug Key Players Head office and Area Served
3.6 Key Players Intracranial Treatment Drug Product Solution and Service
3.7 Date of Enter into Intracranial Treatment Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Intracranial Treatment Drug Breakdown Data by Type
4.1 Global Intracranial Treatment Drug Historic Market Size by Type (2017-2022)
4.2 Global Intracranial Treatment Drug Forecasted Market Size by Type (2023-2028)
5 Intracranial Treatment Drug Breakdown Data by Application
5.1 Global Intracranial Treatment Drug Historic Market Size by Application (2017-2022)
5.2 Global Intracranial Treatment Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Intracranial Treatment Drug Market Size (2017-2028)
6.2 North America Intracranial Treatment Drug Market Size by Type
6.2.1 North America Intracranial Treatment Drug Market Size by Type (2017-2022)
6.2.2 North America Intracranial Treatment Drug Market Size by Type (2023-2028)
6.2.3 North America Intracranial Treatment Drug Market Share by Type (2017-2028)
6.3 North America Intracranial Treatment Drug Market Size by Application
6.3.1 North America Intracranial Treatment Drug Market Size by Application (2017-2022)
6.3.2 North America Intracranial Treatment Drug Market Size by Application (2023-2028)
6.3.3 North America Intracranial Treatment Drug Market Share by Application (2017-2028)
6.4 North America Intracranial Treatment Drug Market Size by Country
6.4.1 North America Intracranial Treatment Drug Market Size by Country (2017-2022)
6.4.2 North America Intracranial Treatment Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Intracranial Treatment Drug Market Size (2017-2028)
7.2 Europe Intracranial Treatment Drug Market Size by Type
7.2.1 Europe Intracranial Treatment Drug Market Size by Type (2017-2022)
7.2.2 Europe Intracranial Treatment Drug Market Size by Type (2023-2028)
7.2.3 Europe Intracranial Treatment Drug Market Share by Type (2017-2028)
7.3 Europe Intracranial Treatment Drug Market Size by Application
7.3.1 Europe Intracranial Treatment Drug Market Size by Application (2017-2022)
7.3.2 Europe Intracranial Treatment Drug Market Size by Application (2023-2028)
7.3.3 Europe Intracranial Treatment Drug Market Share by Application (2017-2028)
7.4 Europe Intracranial Treatment Drug Market Size by Country
7.4.1 Europe Intracranial Treatment Drug Market Size by Country (2017-2022)
7.4.2 Europe Intracranial Treatment Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Intracranial Treatment Drug Market Size (2017-2028)
8.2 Asia-Pacific Intracranial Treatment Drug Market Size by Type
8.2.1 Asia-Pacific Intracranial Treatment Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Intracranial Treatment Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Intracranial Treatment Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Intracranial Treatment Drug Market Size by Application
8.3.1 Asia-Pacific Intracranial Treatment Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Intracranial Treatment Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Intracranial Treatment Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Intracranial Treatment Drug Market Size by Region
8.4.1 Asia-Pacific Intracranial Treatment Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Intracranial Treatment Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Intracranial Treatment Drug Market Size (2017-2028)
9.2 Latin America Intracranial Treatment Drug Market Size by Type
9.2.1 Latin America Intracranial Treatment Drug Market Size by Type (2017-2022)
9.2.2 Latin America Intracranial Treatment Drug Market Size by Type (2023-2028)
9.2.3 Latin America Intracranial Treatment Drug Market Share by Type (2017-2028)
9.3 Latin America Intracranial Treatment Drug Market Size by Application
9.3.1 Latin America Intracranial Treatment Drug Market Size by Application (2017-2022)
9.3.2 Latin America Intracranial Treatment Drug Market Size by Application (2023-2028)
9.3.3 Latin America Intracranial Treatment Drug Market Share by Application (2017-2028)
9.4 Latin America Intracranial Treatment Drug Market Size by Country
9.4.1 Latin America Intracranial Treatment Drug Market Size by Country (2017-2022)
9.4.2 Latin America Intracranial Treatment Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Intracranial Treatment Drug Market Size (2017-2028)
10.2 Middle East & Africa Intracranial Treatment Drug Market Size by Type
10.2.1 Middle East & Africa Intracranial Treatment Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Intracranial Treatment Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Intracranial Treatment Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Intracranial Treatment Drug Market Size by Application
10.3.1 Middle East & Africa Intracranial Treatment Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Intracranial Treatment Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Intracranial Treatment Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Intracranial Treatment Drug Market Size by Country
10.4.1 Middle East & Africa Intracranial Treatment Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Intracranial Treatment Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Details
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Intracranial Treatment Drug Introduction
11.1.4 Novartis AG Revenue in Intracranial Treatment Drug Business (2017-2022)
11.1.5 Novartis AG Recent Developments
11.2 BioMarin
11.2.1 BioMarin Company Details
11.2.2 BioMarin Business Overview
11.2.3 BioMarin Intracranial Treatment Drug Introduction
11.2.4 BioMarin Revenue in Intracranial Treatment Drug Business (2017-2022)
11.2.5 BioMarin Recent Developments
11.3 CORESTEM Inc.
11.3.1 CORESTEM Inc. Company Details
11.3.2 CORESTEM Inc. Business Overview
11.3.3 CORESTEM Inc. Intracranial Treatment Drug Introduction
11.3.4 CORESTEM Inc. Revenue in Intracranial Treatment Drug Business (2017-2022)
11.3.5 CORESTEM Inc. Recent Developments
11.4 Alaunos Therapeutics, Inc.
11.4.1 Alaunos Therapeutics, Inc. Company Details
11.4.2 Alaunos Therapeutics, Inc. Business Overview
11.4.3 Alaunos Therapeutics, Inc. Intracranial Treatment Drug Introduction
11.4.4 Alaunos Therapeutics, Inc. Revenue in Intracranial Treatment Drug Business (2017-2022)
11.4.5 Alaunos Therapeutics, Inc. Recent Developments
11.5 Apic Bio
11.5.1 Apic Bio Company Details
11.5.2 Apic Bio Business Overview
11.5.3 Apic Bio Intracranial Treatment Drug Introduction
11.5.4 Apic Bio Revenue in Intracranial Treatment Drug Business (2017-2022)
11.5.5 Apic Bio Recent Developments
11.6 Stemedica Cell Technologies, Inc.
11.6.1 Stemedica Cell Technologies, Inc. Company Details
11.6.2 Stemedica Cell Technologies, Inc. Business Overview
11.6.3 Stemedica Cell Technologies, Inc. Intracranial Treatment Drug Introduction
11.6.4 Stemedica Cell Technologies, Inc. Revenue in Intracranial Treatment Drug Business (2017-2022)
11.6.5 Stemedica Cell Technologies, Inc. Recent Developments
11.7 Voyager Therapeutics
11.7.1 Voyager Therapeutics Company Details
11.7.2 Voyager Therapeutics Business Overview
11.7.3 Voyager Therapeutics Intracranial Treatment Drug Introduction
11.7.4 Voyager Therapeutics Revenue in Intracranial Treatment Drug Business (2017-2022)
11.7.5 Voyager Therapeutics Recent Developments
11.8 Bayer AG
11.8.1 Bayer AG Company Details
11.8.2 Bayer AG Business Overview
11.8.3 Bayer AG Intracranial Treatment Drug Introduction
11.8.4 Bayer AG Revenue in Intracranial Treatment Drug Business (2017-2022)
11.8.5 Bayer AG Recent Developments
11.9 Abeona Therapeutics
11.9.1 Abeona Therapeutics Company Details
11.9.2 Abeona Therapeutics Business Overview
11.9.3 Abeona Therapeutics Intracranial Treatment Drug Introduction
11.9.4 Abeona Therapeutics Revenue in Intracranial Treatment Drug Business (2017-2022)
11.9.5 Abeona Therapeutics Recent Developments
11.10 Spark Therapeutics
11.10.1 Spark Therapeutics Company Details
11.10.2 Spark Therapeutics Business Overview
11.10.3 Spark Therapeutics Intracranial Treatment Drug Introduction
11.10.4 Spark Therapeutics Revenue in Intracranial Treatment Drug Business (2017-2022)
11.10.5 Spark Therapeutics Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer